Nisa Investment Advisors LLC boosted its stake in shares of Horizon Therapeutics PLC (NASDAQ:HZNP) by 1.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 21,060 shares of the biopharmaceutical company’s stock after purchasing an additional 300 shares during the period. Nisa Investment Advisors LLC’s holdings in Horizon Therapeutics were worth $762,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently bought and sold shares of HZNP. IFP Advisors Inc lifted its stake in Horizon Therapeutics by 163.0% in the 4th quarter. IFP Advisors Inc now owns 1,086 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 673 shares during the last quarter. California State Teachers Retirement System raised its stake in Horizon Therapeutics by 0.4% in the third quarter. California State Teachers Retirement System now owns 292,915 shares of the biopharmaceutical company’s stock valued at $7,976,000 after buying an additional 1,095 shares during the period. Bank of Montreal Can raised its stake in Horizon Therapeutics by 45.7% in the second quarter. Bank of Montreal Can now owns 3,831 shares of the biopharmaceutical company’s stock valued at $92,000 after buying an additional 1,201 shares during the period. Regent Investment Management LLC raised its stake in Horizon Therapeutics by 0.9% in the third quarter. Regent Investment Management LLC now owns 130,335 shares of the biopharmaceutical company’s stock valued at $3,549,000 after buying an additional 1,225 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Horizon Therapeutics by 16.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,497 shares of the biopharmaceutical company’s stock valued at $313,000 after buying an additional 1,587 shares during the last quarter. Hedge funds and other institutional investors own 88.15% of the company’s stock.
A number of research analysts recently weighed in on HZNP shares. Morgan Stanley boosted their target price on Horizon Therapeutics from $32.00 to $38.00 and gave the stock an “overweight” rating in a report on Monday, December 16th. BidaskClub raised Horizon Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 28th. Jefferies Financial Group lifted their price objective on shares of Horizon Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. Piper Jaffray Companies reiterated a “buy” rating and issued a $49.00 price objective (up from $36.00) on shares of Horizon Therapeutics in a report on Tuesday, December 24th. Finally, Zacks Investment Research lowered shares of Horizon Therapeutics from a “buy” rating to a “hold” rating and set a $31.00 price objective on the stock. in a research report on Tuesday, October 29th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $37.57.
In other news, EVP Vikram Karnani sold 9,297 shares of Horizon Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $35.62, for a total value of $331,159.14. Following the completion of the sale, the executive vice president now directly owns 92,654 shares in the company, valued at $3,300,335.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Brian K. Beeler sold 12,475 shares of Horizon Therapeutics stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $30.02, for a total transaction of $374,499.50. The disclosure for this sale can be found here. In the last three months, insiders sold 126,888 shares of company stock valued at $4,413,598. 4.10% of the stock is currently owned by company insiders.
HZNP opened at $36.03 on Tuesday. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.33 and a quick ratio of 2.23. The business has a fifty day simple moving average of $36.07 and a 200 day simple moving average of $29.70. Horizon Therapeutics PLC has a 1 year low of $20.05 and a 1 year high of $39.10. The company has a market capitalization of $6.75 billion, a PE ratio of 97.38, a price-to-earnings-growth ratio of 1.53 and a beta of 0.89.
Horizon Therapeutics (NASDAQ:HZNP) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.14. Horizon Therapeutics had a return on equity of 27.71% and a net margin of 5.25%. The firm had revenue of $335.50 million for the quarter, compared to analysts’ expectations of $330.60 million. During the same quarter last year, the business earned $0.65 EPS. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. Equities analysts anticipate that Horizon Therapeutics PLC will post 1.55 earnings per share for the current fiscal year.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Read More: Dividend Stocks – Are They Right For You?
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.